Premal Shah

Premal Shah is the CEO of MyOme. Prior to this, Shah was with InterVenn Biosciences and Booz & Company. Shah has over fifteen years of experience in the pharmaceutical and healthcare industries.

Shah started their career at Booz & Company in 2006 as an Engagement Manager / Senior Associate. Premal quickly rose through the ranks and became a leading member of the team. Some of their notable projects include leading a team to due diligence for a German-based client looking to enter the U.S. generic pharmaceutical market and managing a team to identify over 15% cost reductions in R&D operations for a leading over-the-counter pharmaceutical company.

In 2010, Shah left Booz & Company to join InterVenn Biosciences. Premal was responsible for developing and executing the company's informatics strategy. Premal also advised on the consolidation of drug safety organizations, which resulted in over 20% in cost savings.

In 2016, Shah was appointed CEO of MyOme. Under their leadership, the company has seen significant growth and expansion.

Premal Shah has a Ph.D in Biochemistry & Molecular Biophysics from Caltech and a Bachelor of Science in Biochemistry and Molecular Biology from the University of Maryland Baltimore County.

Donna Hongo - Head Of Quality & Regulatory, Brynn Levy - Clinical Laboratory Director, and Kate Im - Genetics Lead & Co-Founder report to Premal Shah.